Poxel: Postponement of the Publication of the 2025 Annual Financial Statements and the Annual Financial Report

LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical company that leverages its expertise to develop innovative treatments for metabolic diseases, including certain rare diseases (the “Company”), announces the postponement of the publication of its annual financial statements for the fiscal year ended December 31, 2025, and its 2025 annual financial report. This decision is related to the completion, since the Lyon Commercial Court appro.